Comerț Arvinas Inc - ARVN CFD

Condiții de tranzacționare

• Tip:
  CFD

  

  Knock-out

  
• Ecart minim: 0.14
• Ajustarea finanțării peste noapte a poziției lungi: -0.02162%
• Ajustarea finanțării peste noapte a poziției scurte: -0.00060%
• Oră ajustare finanțare peste noapte: 22:00 (UTC)
• Monedă: USD
• Cantitate minimă tranzacționată: 1
• Marjă: 50.00%
• Bursă: United States of America
• Comision tranzacționare: 0%
• Prima de oprire garantată: 1%

Statistici cheie

• Închis anterior: 13.22
• Deschidere: 12.75
• Schimbare la 1 an: -27.47%
• Interval zi: 12.56 - 13.27

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Bayer AG, and Insilico Medicine, Inc. Arvinas, Inc. was incorporated in 2013 and is based in New Haven, Connecticut.